Small-molecule agents for cancer immunotherapy

Fang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Liwu Fu(Sun Yat-sen University), Yujue Wang(Center for Life Sciences), Kenneth K.W. To(Riverview Hospital), Zhi Shi(University of Jinan), Chenglai Xia(Foshan Maternity and Child Health Care Hospital), Zeping Hu(King Center), Xiaopeng Li(Zhengzhou Central Hospital), Zeyu Liu(Third Affiliated Hospital of Southern Medical University), Xue‐Ping Wang(Sun Yat-sen University), Jianye Zhang(Shanghai Mental Health Center), Min Huang(Chinese Academy of Sciences), Chuan Yang(Sun Yat-sen University), Kai Fu(Nanjing Medical University), Yu Lu(Children's Hospital of Capital Institute of Pediatrics), Can Pan(Sun Yat-sen University), Ying Zheng(Chinese Academy of Sciences)
Acta Pharmaceutica Sinica B
December 15, 2023
10.1016/j.apsb.2023.12.010
Cited by 53

Related Papers

Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
KRAS mutation: from undruggable to druggable in cancer
|Signal Transduction and Targeted Therapy|2021|1k
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|385
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
|Cancer Research|2010|348
Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications
|Nature Communications|2021|319